Form 4: Actinium CEO's Future Stock Sale for Tax Obligations

Actinium Pharmaceuticals CEO Sandesh Seth will dispose of 120,900 shares of common stock on August 18, 2025, to cover tax obligations from RSU vesting.

Summary

• Sandesh Seth, Chief Executive Officer and Director of Actinium Pharmaceuticals, Inc. (ATNM), will dispose of 120,900 shares of common stock.
• The transaction is scheduled for August 18, 2025, at a price of $1.71 per share.
• This disposition is specifically to satisfy tax withholding obligations incurred in connection with the vesting of 300,000 restricted stock units (RSUs).
• Following this reported transaction, Mr. Seth will beneficially own 184,481 shares directly.
• The 300,000 RSUs were granted on August 17, 2022, in exchange for warrants originally granted to Mr. Seth on December 17, 2012, for services provided prior to his employment.
• The warrants were 'in the money' since vesting on December 17, 2013, but Mr. Seth refrained from exercising them to align with the long-term interests of the Company and stockholders.
• In November 2018, the Board extended the expiration of Mr. Seth's warrants to February 2022, and in February 2022, the Company requested he not exercise them, leading to the RSU grant based on the average fair value of the warrants.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction itself is a routine tax-related disposition of shares upon equity vesting. The underlying history of the RSU grant, replacing warrants that the CEO refrained from exercising, suggests a positive alignment of management's long-term interests with the company and its shareholders.

Positives

• Management (CEO Sandesh Seth) demonstrated alignment with long-term company and stockholder interests by refraining from exercising 'in the money' warrants for an extended period.
• The grant of 300,000 RSUs to the CEO reinforces continued alignment with the long-term performance and strategic objectives of the company.

Negatives

• Disposition of 120,900 shares of common stock by the CEO, even for tax purposes, results in a reduction of his direct share ownership.

Future Outlook

This filing is a report of an insider transaction for equity compensation and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Mr. Seth refrained from exercising the warrants to be aligned with the long-term interests of the Company and stockholders.
• In exchange, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life to continue to align Mr. Seth with the long-term interest of the Company and stockholders.

Industry Context

This is a routine insider transaction related to executive equity compensation, a common practice across all industries. It reflects the mechanics of how executives realize value from their compensation packages and manage associated tax liabilities, rather than indicating specific industry trends or competitive dynamics.

Corporate Governance

Related Party Transactions

• The grant of 300,000 RSUs to CEO Sandesh Seth on August 17, 2022, in exchange for previously held warrants, where the company requested non-exercise of the warrants, constitutes a related party transaction involving executive compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related disposition following equity vesting, which is generally expected. The underlying RSU grant and its history suggest management's long-term alignment, which could be viewed positively.
• Management: CEO Sandesh Seth's equity compensation is being realized, with a portion withheld for taxes. His continued equity holdings maintain alignment with company performance.

Key Dates

Keywords

Actinium Pharmaceuticals, ATNM, Sandesh Seth, CEO, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation, Corporate Governance